Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide; Drug: Cefpodoxime; Drug: Cefixime Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Condition: Refractory Solid Tumors Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
